News

Yahoo Finance

Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

*Baseline is referred to as start of HOPE-2 OLE study, changes in means are shown “I am extremely encouraged by these positive results from our HOPE-2 OLE study which continue to support the long-term ...
Yahoo Finance

Capricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the ...